DE602006014949D1 - Phosphoramidatderivate von nukleosidverbindungen zur verwendung bei der behandlung von krebs - Google Patents

Phosphoramidatderivate von nukleosidverbindungen zur verwendung bei der behandlung von krebs

Info

Publication number
DE602006014949D1
DE602006014949D1 DE602006014949T DE602006014949T DE602006014949D1 DE 602006014949 D1 DE602006014949 D1 DE 602006014949D1 DE 602006014949 T DE602006014949 T DE 602006014949T DE 602006014949 T DE602006014949 T DE 602006014949T DE 602006014949 D1 DE602006014949 D1 DE 602006014949D1
Authority
DE
Germany
Prior art keywords
cancer
treatment
nucleoside compounds
phosphoramidate derivatives
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602006014949T
Other languages
German (de)
English (en)
Inventor
Christopher Mcguigan
Kenneth Mills
Costantino Congiatu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cardiff Protides Ltd
Original Assignee
Cardiff Protides Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cardiff Protides Ltd filed Critical Cardiff Protides Ltd
Publication of DE602006014949D1 publication Critical patent/DE602006014949D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16Purine radicals
    • C07H19/20Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DE602006014949T 2005-03-21 2006-03-16 Phosphoramidatderivate von nukleosidverbindungen zur verwendung bei der behandlung von krebs Active DE602006014949D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0505781.5A GB0505781D0 (en) 2005-03-21 2005-03-21 Chemical compounds
PCT/GB2006/000932 WO2006100439A1 (en) 2005-03-21 2006-03-16 Phosphoramidate derivatives of nucleoside compounds for use in the treatment of cancer

Publications (1)

Publication Number Publication Date
DE602006014949D1 true DE602006014949D1 (de) 2010-07-29

Family

ID=34531603

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602006014949T Active DE602006014949D1 (de) 2005-03-21 2006-03-16 Phosphoramidatderivate von nukleosidverbindungen zur verwendung bei der behandlung von krebs

Country Status (20)

Country Link
US (1) US8263575B2 (enExample)
EP (1) EP1866324B1 (enExample)
JP (2) JP5345381B2 (enExample)
CN (2) CN101175763A (enExample)
AT (1) ATE471334T1 (enExample)
AU (1) AU2006226182C1 (enExample)
BR (1) BRPI0609704B8 (enExample)
CA (1) CA2602324C (enExample)
CY (1) CY1111538T1 (enExample)
DE (1) DE602006014949D1 (enExample)
DK (1) DK1866324T3 (enExample)
ES (1) ES2348741T3 (enExample)
GB (1) GB0505781D0 (enExample)
IL (1) IL186104A (enExample)
MX (1) MX2007011666A (enExample)
PL (1) PL1866324T3 (enExample)
PT (1) PT1866324E (enExample)
SI (1) SI1866324T1 (enExample)
WO (1) WO2006100439A1 (enExample)
ZA (1) ZA200709011B (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0623493D0 (en) * 2006-11-24 2007-01-03 Univ Cardiff Chemical compounds
AU2012216500B2 (en) * 2006-11-24 2013-06-20 Katholieke Universiteit Leuven Nucleoside aryl phosphoramidates and their use as anti-viral agents for the treatment of hepatitis C virus
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
US8716263B2 (en) 2008-12-23 2014-05-06 Gilead Pharmasset Llc Synthesis of purine nucleosides
US8551973B2 (en) 2008-12-23 2013-10-08 Gilead Pharmasset Llc Nucleoside analogs
PA8855601A1 (es) 2008-12-23 2010-07-27 Forformidatos de nucleósidos
CA2749394A1 (en) 2009-01-09 2010-07-15 University College Of Cardiff Consultants Limited Phosphoramidate derivatives of guanosine nucleoside compounds for treatment of viral infections
WO2011123668A2 (en) 2010-03-31 2011-10-06 Pharmasset, Inc. Stereoselective synthesis of phosphorus containing actives
GB201016855D0 (en) * 2010-10-06 2010-11-17 Nucana Biomed Ltd Chemical compounds
US9351989B2 (en) 2010-12-29 2016-05-31 Inhibitex, Inc. Substituted purine nucleosides, phosphoroamidate and phosphorodiamidate derivatives for treatment of viral infections
CN103403014B (zh) * 2011-01-03 2016-07-06 河南美泰宝生物制药有限公司 O-(经取代的苯甲基)氨基磷酸酯化合物及其治疗用途
HRP20160346T1 (hr) * 2011-03-01 2016-05-06 Nucana Biomed Limited Fosforoamidatni derivati 5-fluoro-2'-deoksiuridina za upotrebu u tretmanu raka
US9085599B2 (en) 2011-03-16 2015-07-21 Enanta Pharmaceuticals, Inc. 2′allene-substituted nucleoside derivatives
ES2627195T3 (es) 2012-11-16 2017-07-27 University College Cardiff Consultants Limited Mezcla de RP/SP gemcitabina-[fenil-(bencloxi-l-alaninil)]-fosfato
US10005779B2 (en) 2013-06-05 2018-06-26 Idenix Pharmaceuticals Llc 1′,4′-thio nucleosides for the treatment of HCV
KR20160099090A (ko) * 2013-11-27 2016-08-19 아이데닉스 파마슈티칼스 엘엘씨 간암의 치료를 위한 뉴클레오티드
CA2947939A1 (en) * 2014-05-28 2015-12-03 Idenix Pharmaceuticals Llc Nucleoside derivatives for the treatment of cancer
CN106459127A (zh) * 2014-05-28 2017-02-22 艾登尼克斯药业有限公司 用于治疗癌症的核苷衍生物
KR102548806B1 (ko) 2014-11-28 2023-06-27 뉴카나 피엘씨 항암제로서 새로운 2' 및/또는 5' 아미노산 에스테르 포스포르아미데이트 3'-디옥시아데노신 유도체
WO2016144918A1 (en) 2015-03-06 2016-09-15 Atea Pharmaceuticals, Inc. β-D-2'-DEOXY-2'α-FLUORO-2'-β-C-SUBSTITUTED-2-MODIFIED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT
CN108431016A (zh) * 2015-11-16 2018-08-21 艾可瑞恩治疗公司 核酸前体药物
GB201522764D0 (en) * 2015-12-23 2016-02-03 Nucana Biomed Ltd Formulations of phosphate derivatives
GB201609602D0 (en) * 2016-06-01 2016-07-13 Nucuna Biomed Ltd Chemical compounds
GB201609600D0 (en) 2016-06-01 2016-07-13 Nucuna Biomed Ltd Cancer treatments
GB201609601D0 (en) * 2016-06-01 2016-07-13 Nucana Biomed Ltd Phosphoramidate compounds
US10711029B2 (en) 2016-07-14 2020-07-14 Atea Pharmaceuticals, Inc. Beta-d-2′-deoxy-2′-alpha-fluoro-2′-beta-c-substituted-4′fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection
SG11201901457TA (en) 2016-09-07 2019-03-28 Atea Pharmaceuticals Inc 2'-substituted-n6-substituted purine nucleotides for rna virus treatment
US11202792B2 (en) * 2016-10-12 2021-12-21 Georgetown University CD99 inhibitors and their uses
GB201709471D0 (en) 2017-06-14 2017-07-26 Nucana Biomed Ltd Diastereoselective synthesis of hosphate derivatives
GB201715011D0 (en) 2017-09-18 2017-11-01 Nucana Biomed Ltd Floxuridine synthesis
GB201720279D0 (en) 2017-12-05 2018-01-17 Nucana Biomed Ltd Anticancer compounds
JP2020164521A (ja) * 2019-03-29 2020-10-08 国立大学法人 長崎大学 抗ウィルス薬
GB201904544D0 (en) 2019-04-01 2019-05-15 NuCana plc Anticancer compounds
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19
WO2021173713A1 (en) 2020-02-27 2021-09-02 Atea Pharmaceuticals, Inc. Highly active compounds against covid-19
CN113549076B (zh) * 2021-07-23 2022-12-06 中国药科大学 一种多取代嘌呤类化合物及其制备方法和应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR880000094B1 (ko) 1984-12-07 1988-02-23 보령제약 주식회사 뉴클레오시드 유도체의 제조방법
CA2004695C (en) 1988-12-12 1999-08-10 Rosanne Bonjouklian Phospholipid nucleosides
DE4418690A1 (de) 1994-05-28 1996-01-11 Boehringer Mannheim Gmbh Neue Lipidester von Nucleosid-Monophosphaten und deren Verwendung als immunsuppressive Arzneimittel
GB9505025D0 (en) * 1995-03-13 1995-05-03 Medical Res Council Chemical compounds
JP4313847B2 (ja) * 1995-04-21 2009-08-12 ユニヴァーシティ オブ サウス フロリダ 免疫賦活性イノシン一リン酸の5’−ヌクレオチダーゼ抵抗性誘導体およびその使用
JP3761958B2 (ja) * 1996-03-12 2006-03-29 彰 松田 3′−カルバモイルアルキルヌクレオシド誘導体
ES2172303T3 (es) * 1998-01-23 2002-09-16 Newbiotics Inc Agentes terapeuticos obtenidos por catalisis enzimatica.
GB9821058D0 (en) * 1998-09-28 1998-11-18 Univ Cardiff Chemical compound
JP4768909B2 (ja) * 2000-09-29 2011-09-07 扶桑薬品工業株式会社 トポイソメラーゼ阻害剤
US20030073618A1 (en) 2001-02-08 2003-04-17 Kozhemyakin Leonid A. Compounds comprising disulfide-containing peptides and nitrogenous bases, and medical uses thereof
DE10108851A1 (de) * 2001-02-23 2002-09-12 Resprotect Gmbh Verwendung von 5'-substituierten Nukleosiden und/oder deren Prodrugs zur resistenzfreien Therapie von Infektionskrankheiten
BR0210594A (pt) 2001-06-22 2005-11-01 Pharmasset Ltd (beta)-d ou (beta)-l-3-halonucleosìdeo
GB0317009D0 (en) * 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
GB0401088D0 (en) 2004-01-19 2004-02-18 Univ Cardiff Phosphoramidate derivatives
AU2005267421B2 (en) * 2004-06-24 2010-06-03 Merck Sharp & Dohme Corp. Nucleoside aryl phosphoramidates for the treatment of RNA-dependent RNA viral infection
CN101287472B (zh) * 2005-08-15 2011-10-12 弗·哈夫曼-拉罗切有限公司 抗病毒的4'-取代前核苷酸的氨基磷酸酯类化合物

Also Published As

Publication number Publication date
AU2006226182A1 (en) 2006-09-28
WO2006100439A1 (en) 2006-09-28
GB0505781D0 (en) 2005-04-27
PL1866324T3 (pl) 2010-12-31
ATE471334T1 (de) 2010-07-15
JP2013173786A (ja) 2013-09-05
MX2007011666A (es) 2007-11-14
CA2602324A1 (en) 2006-09-28
BRPI0609704A2 (pt) 2010-04-20
ZA200709011B (en) 2009-01-28
BRPI0609704B1 (pt) 2020-12-01
CA2602324C (en) 2015-02-24
CN101175763A (zh) 2008-05-07
JP5345381B2 (ja) 2013-11-20
DK1866324T3 (da) 2010-09-27
PT1866324E (pt) 2010-09-16
AU2006226182C1 (en) 2012-06-14
EP1866324A1 (en) 2007-12-19
IL186104A0 (en) 2008-01-20
JP5863702B2 (ja) 2016-02-17
CN103936807A (zh) 2014-07-23
US20090215715A1 (en) 2009-08-27
JP2008533191A (ja) 2008-08-21
US8263575B2 (en) 2012-09-11
CY1111538T1 (el) 2015-08-05
SI1866324T1 (sl) 2010-10-29
IL186104A (en) 2013-06-27
ES2348741T3 (es) 2010-12-13
BRPI0609704B8 (pt) 2021-09-28
EP1866324B1 (en) 2010-06-16
AU2006226182B2 (en) 2011-09-01

Similar Documents

Publication Publication Date Title
ATE471334T1 (de) Phosphoramidatderivate von nukleosidverbindungen zur verwendung bei der behandlung von krebs
ATE404574T1 (de) Verfahren zur inhibierung der proliferation von tumorzellen, bei dem platinkomplexe eingesetzt werden
ECSP088440A (es) Imidazopirazinas como inhibidores de proteinquinasa
TW200716141A (en) Compositions and methods for treatment for neoplasms
EA201692543A1 (ru) Антагонисты активина-actriia и их применение для стимулирования роста кости
CY1109741T1 (el) Sns-595 και μεθοδοι χρησης αυτου
TR200906131T1 (tr) Aktivin -actrIIa antagonistleri ve göğüs kanserinin tedavi e
BRPI0513310A (pt) análogos de tetrapeptìdeo
CY1113963T1 (el) Φαρμακευτικες συνθεσεις οι οποιες περιλαμβανουν ανταγωνιστες ακτιβινης-actriia και χρηση αυτων στην προληψη η' θεραπευτικη αγωγη πολλαπλου μυελωματος
CY1126007T1 (el) Προαγωγεις αποπτωσης
TW200801008A (en) Protein kinase inhibitors
EP4023299C0 (en) 5-FLUORO-2'-DEOXYURIDINE PHOSPHORAMIDATE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER
ATE554114T1 (de) Copolymer mit zwitterionischen einheiten und anderen einheiten, das copolymer umfassende zusammensetzung und verwendung
CY1112743T1 (el) Στερεοϊσομερως εμπλουτισμενες ενωσεις 3-αμινοκαρβονυλ δικυκλοεπτενο πυριμιδινοδιαμινης και οι χρησεις τους
DE602006018709D1 (de) Estergebundene geminitensidverbindungen zur verwendung in der gentherapie
DE602004031134D1 (de) Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa
ATE527241T1 (de) Pyridiazinonderivate zur behandlung von tumoren
DE502006005290D1 (de) Niedrigviskose uretdiongruppenhaltige polyadditionsverbindungen, verfahren zur herstellung und verwendung
NO20082425L (no) Formuleringer omfattende jorumycin-, reni-eramycin-, safracin- eller saframycin-relaterte forbindelser for behandling av proliferative sykdommer
WO2009009034A3 (en) Methods and compositions useful in the treatment of mucositis
MX2010005324A (es) Composiciones y metodos para inhibir el avance del tumor.
EP1863520A4 (en) USE OF INTERLEUKIN 17E FOR THE TREATMENT OF CANCER
ATE397000T1 (de) Tetrahydropyridothiophenen zur verwendung in der behandlung von krebs
DE602006003094D1 (de) 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydrochinolin-derivate zur behandlung von unfruchtbarkeit
DK1606233T3 (da) Phospholipidestere af Clofarabin